The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.

摘要: It was reported that DNA repair can confer cancer cell resistance to therapeutic treatments by activating antiapoptotic cellular defense. We hypothesized genetic variants of genes may be associated with lung prognosis. Seventeen tagging single-nucleotide polymorphism (tagSNPs) selected from 12 were genotyped in 280 advanced non-small-cell (NSCLC) patients TaqMan assay. The associations these SNPs and overall survival NSCLC investigated. Advanced carrying ERCC2 rs50872 CT+TT genotypes had significantly longer median time (MST) decreased death risk than CC genotype [log-rank P = 0.031; adjusted HR(95% CI) = 0.73 (0.55-0.98), P = 0.033]. These effects mainly seen among younger (≤65 years old) [HR(95% CI) = 0.57 (0.37-0.87), P = 0.010], without surgery CI) = 0.68 (0.47-0.98), P = 0.036] but chemotherapy CI) = 0.64 (0.46-0.91), P = 0.012] or radiotherapy CI) = 0.58 (0.38-0.89), P = 0.013]. Meanwhile, compared rs25487 GG genotype, XRCC1 GA+AA shorter MST (MST = 11.7 vs. 16.7, log-rank P = 0.048). In addition, the combination shortest (11.2 month) highest CI) = 1.70 (1.15-2.52), P = 0.008] when those (MST = 22.0 month). T allele favorable A bad for Chinese population, which offer novel biomarkers predicting clinical outcomes.